Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment of Newly Diagnosed Patients with High-Risk APL By Ogkologos - September 3, 2025 477 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the APOLLO study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer October 26, 2021 EMA Recommends Granting a Marketing Authorisation for Fruquintinib May 13, 2024 Trastuzumab Deruxtecan Shows Antitumour Activity and Durable Responses in Heavily Pretreated... May 16, 2024 Mammograms Can Detect COVID-19 Vaccination Swelling, Causing Cancer Scares March 4, 2021 Load more HOT NEWS The future of research: meet three of our scientists working on... Receiving a Blood Transfusion During Cancer: What to Know and What... Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical... Cancer in My Community: Addressing Regional Cancer Disparities in Peru
